Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial
Toshiaki Ohkuma, Min Jun, Anthony Rodgers, Mark E Cooper, Paul Glasziou, Pavel Hamet, Stephen Harrap, Giuseppe Mancia, Michel Marre, Bruce Neal, Vlado Perkovic, Neil Poulter, Bryan Williams, Sophia Zoungas, John Chalmers, Mark Woodward
HYPERTENSION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
Discontinuation of angiotensin-converting enzyme (ACE) inhibitor is recommended if patients experience ≥30% acute increase in serum creatinine after starting this therapy. However, the long-term effects of its continuation or discontinuation on major clinical outcomes after increases in serum creatinine are unclear. In the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation), 11 140 diabetes mellitus patients were randomly assigned to perindopril-indapamide or placebo after a 6-week active run-in period. The current study included 11 066 participants with 2 serum creatinine measurements recorded before and during the active ru..View full abstract
The ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) was funded by the grants from the National Health and Medical Research Council (NHMRC) of Australia and Servier. T. Ohkuma is supported by the John Chalmers Clinical Research Fellowship of the George Institute. M. Jun is supported by a Scientia Fellowship from the University of New South Wales Sydney. B. Williams is a National Institute for Health Research (NIHR) Senior Investigator. M. Woodward is an NHMRC of Australia Principal Research Fellow (1080206).